IL161041A0 - Mch antagonists for the treatment of obesity - Google Patents
Mch antagonists for the treatment of obesityInfo
- Publication number
- IL161041A0 IL161041A0 IL16104102A IL16104102A IL161041A0 IL 161041 A0 IL161041 A0 IL 161041A0 IL 16104102 A IL16104102 A IL 16104102A IL 16104102 A IL16104102 A IL 16104102A IL 161041 A0 IL161041 A0 IL 161041A0
- Authority
- IL
- Israel
- Prior art keywords
- obesity
- treatment
- mch antagonists
- mch
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34306501P | 2001-10-25 | 2001-10-25 | |
PCT/US2002/033869 WO2003035055A1 (fr) | 2001-10-25 | 2002-10-23 | Antagonistes de mch utilises pour traiter l'obesite |
Publications (1)
Publication Number | Publication Date |
---|---|
IL161041A0 true IL161041A0 (en) | 2004-08-31 |
Family
ID=23344534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16104102A IL161041A0 (en) | 2001-10-25 | 2002-10-23 | Mch antagonists for the treatment of obesity |
Country Status (13)
Country | Link |
---|---|
US (1) | US7045636B2 (fr) |
EP (1) | EP1443922A1 (fr) |
JP (2) | JP4643141B2 (fr) |
KR (1) | KR20040047935A (fr) |
CN (1) | CN100548291C (fr) |
AR (1) | AR036939A1 (fr) |
AU (1) | AU2002337956B2 (fr) |
CA (1) | CA2464130C (fr) |
HU (1) | HUP0401656A3 (fr) |
IL (1) | IL161041A0 (fr) |
MX (1) | MXPA04003858A (fr) |
WO (1) | WO2003035055A1 (fr) |
ZA (1) | ZA200403087B (fr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002352878B2 (en) | 2001-11-27 | 2007-11-22 | Merck Sharp & Dohme Corp. | 2-Aminoquinoline compounds |
EP1451156A4 (fr) * | 2001-11-27 | 2005-05-25 | Merck & Co Inc | Composes 4-aminoquinoleines |
DE10250743A1 (de) * | 2002-10-31 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
US7351719B2 (en) * | 2002-10-31 | 2008-04-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds |
JPWO2004069798A1 (ja) * | 2003-02-10 | 2006-05-25 | 萬有製薬株式会社 | ピペリジン誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤 |
CA2540826A1 (fr) | 2003-10-01 | 2005-04-14 | The Procter & Gamble Company | Antagonistes de l'hormone concentrant la melanine |
US7592373B2 (en) | 2003-12-23 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
DE102004017934A1 (de) | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
US7524862B2 (en) | 2004-04-14 | 2009-04-28 | Boehringer Ingelheim International Gmbh | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
TW200630337A (en) * | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
WO2006104136A1 (fr) * | 2005-03-29 | 2006-10-05 | Banyu Pharmaceutical Co., Ltd. | Agent thérapeutique pour maladie adipeuse hépatique non alcoolique, et méthode de sélection de composé candidat médicamenteux pour le traitement ou la prévention de maladie adipeuse hépatique non alcoolique |
EP2258358A3 (fr) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenèse avec un inhibiteur de l'acetylcholinestérase |
CA2620333A1 (fr) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenese par modulation du recepteur muscarinique |
EP1940389A2 (fr) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation de la neurogenese par inhibition de la pde |
CA2625210A1 (fr) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Modulation de la neurogenese dont la mediation est assuree par recepteur gaba |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
WO2007110449A1 (fr) * | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Composés de benzènesulfonamide et utilisation de ceux-ci |
US8791264B2 (en) * | 2006-04-13 | 2014-07-29 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
WO2007118854A1 (fr) * | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Composés à base de benzènesulfonamide et leur utilisation |
US7858611B2 (en) * | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
MX2009002496A (es) | 2006-09-08 | 2009-07-10 | Braincells Inc | Combinaciones que contienen un derivado de 4-acilaminopiridina. |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
WO2008083204A2 (fr) * | 2006-12-28 | 2008-07-10 | Braincells, Inc. | Modulation de la neurogenèse par des ligands mélatoninergiques |
EP2125017A2 (fr) * | 2007-01-11 | 2009-12-02 | Braincells, Inc. | Modulation de la neurogenèse en utilisant du modafinil |
JP4735719B2 (ja) * | 2007-03-29 | 2011-07-27 | パナソニック株式会社 | 受信装置とこれを用いた電子機器 |
WO2008124118A1 (fr) * | 2007-04-09 | 2008-10-16 | Purdue Pharma L.P. | Composés benzènesulfonylés et leur utilisation |
US8765736B2 (en) * | 2007-09-28 | 2014-07-01 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
WO2009128058A1 (fr) | 2008-04-18 | 2009-10-22 | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al | Produits psycho-pharmaceutiques |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5908830A (en) | 1996-10-31 | 1999-06-01 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes and obesity |
US6245746B1 (en) | 1998-01-23 | 2001-06-12 | Microcide Pharmaceuticals, Inc. | Efflux pump inhibitors |
EP1219294A4 (fr) * | 1999-09-20 | 2005-01-26 | Antagonistes de l'hormone de concentration de la melanine | |
US20030022891A1 (en) * | 2000-12-01 | 2003-01-30 | Anandan Palani | MCH antagonists and their use in the treatment of obesity |
MXPA03009353A (es) * | 2001-04-12 | 2004-02-12 | Pharmacopeia Inc | Aril y biaril piperidinas utilizadas como antagonistas de mch. |
-
2002
- 2002-10-23 AU AU2002337956A patent/AU2002337956B2/en not_active Ceased
- 2002-10-23 KR KR10-2004-7005832A patent/KR20040047935A/ko not_active Application Discontinuation
- 2002-10-23 AR ARP020104004A patent/AR036939A1/es unknown
- 2002-10-23 JP JP2003537622A patent/JP4643141B2/ja not_active Expired - Fee Related
- 2002-10-23 CA CA2464130A patent/CA2464130C/fr not_active Expired - Fee Related
- 2002-10-23 IL IL16104102A patent/IL161041A0/xx unknown
- 2002-10-23 MX MXPA04003858A patent/MXPA04003858A/es active IP Right Grant
- 2002-10-23 US US10/278,468 patent/US7045636B2/en not_active Expired - Fee Related
- 2002-10-23 EP EP02773861A patent/EP1443922A1/fr not_active Withdrawn
- 2002-10-23 CN CNB028210697A patent/CN100548291C/zh not_active Expired - Fee Related
- 2002-10-23 HU HU0401656A patent/HUP0401656A3/hu unknown
- 2002-10-23 WO PCT/US2002/033869 patent/WO2003035055A1/fr active Application Filing
-
2004
- 2004-04-22 ZA ZA200403087A patent/ZA200403087B/en unknown
-
2010
- 2010-02-16 JP JP2010031848A patent/JP2010155848A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
MXPA04003858A (es) | 2004-07-08 |
JP4643141B2 (ja) | 2011-03-02 |
CN100548291C (zh) | 2009-10-14 |
EP1443922A1 (fr) | 2004-08-11 |
CA2464130A1 (fr) | 2003-05-01 |
AR036939A1 (es) | 2004-10-13 |
AU2002337956B2 (en) | 2006-02-23 |
KR20040047935A (ko) | 2004-06-05 |
US20030144261A1 (en) | 2003-07-31 |
CA2464130C (fr) | 2010-12-21 |
HUP0401656A2 (hu) | 2004-12-28 |
ZA200403087B (en) | 2005-04-22 |
US7045636B2 (en) | 2006-05-16 |
JP2005507918A (ja) | 2005-03-24 |
CN1575169A (zh) | 2005-02-02 |
HUP0401656A3 (en) | 2012-05-02 |
JP2010155848A (ja) | 2010-07-15 |
WO2003035055A1 (fr) | 2003-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL161041A0 (en) | Mch antagonists for the treatment of obesity | |
AU2003285091A8 (en) | Interferon antagonists useful for the treatment of interferon related diseases | |
IL159344A0 (en) | Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease | |
EP1446445A4 (fr) | Agents porogenes pour ciments orthopediques | |
IL159347A0 (en) | Arylamines for the treatment of conditions associated with gsk-3 | |
EP1534074A4 (fr) | Polytherapie pour le traitement de l'obesite | |
GB0112343D0 (en) | Well treatment | |
ZA200305691B (en) | The use of substituted azetidione compounds for the treatment of sitosterolemia | |
HUS2200036I1 (hu) | Dihidroimidazolonok alkalmazása kutyák kezelésére | |
IL162311A0 (en) | N-aryl-n'-arylcycloalkyl-urea derivatives aas mch antagonists for the treatment of obesity | |
AU2003258145A8 (en) | Substituted phenylindoles for the treatment of hiv | |
IL157145A0 (en) | Use of dc23 antagonists for the treatment of neoplastic disorders | |
AU2003279841A8 (en) | Uses of human zven antagonists | |
EP1461030A4 (fr) | Composes d'aminoalkyl-benzofuran-5-ol pour le traitement du glaucome | |
PL375564A1 (en) | Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma | |
IL161748A0 (en) | New use for the treatment of gastroesophageal reflux | |
GB0130219D0 (en) | Compounds for the treatment of sexual dysfunction | |
AU2003259074A8 (en) | Gal3 antagonists for the treatment of neuropathic pain | |
AU2003273856A8 (en) | Vr1 antagonists for the treatment of urological disorders | |
AU2002336782A8 (en) | Penis vibrator | |
AU2003240174A8 (en) | Compositions for the treatment of edematous-firbrosclerotic panniculopathy | |
SI1451177T1 (sl) | Substituirani 2-pirolidin-2-il-1H-indolni derivati za zdravljenje migrene | |
AU2002366272A8 (en) | Edg-receptor agonist for the treatment of hypertension | |
AU2003300867A8 (en) | Uses of the snorf207 receptor | |
AU2003245995A8 (en) | Use of gaba-c receptor antagonists for the treatment of myopia |